Nanobiotix SA (FR:NANO)
:NANO
Want to see FR:NANO full AI Analyst Report?
NANO Stock Chart & Stats
€28.70
<€0.01(0.14%)
At close: 4:00 PM EST
€28.70
<€0.01(0.14%)
Day’s Range― - ―
52-Week Range€3.76 - €47.66
Previous CloseN/A
Volume30.64K
Average Volume (3M)654.19K
Market Cap
€1.53B
Enterprise Value€1.60B
Total Cash (Recent Filing)€52.75M
Total Debt (Recent Filing)€95.32M
Price to Earnings (P/E)―
Beta0.72
Next Earnings
Sep 30, 2026EPS Estimate
-0.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.51
Shares Outstanding50,619,583
10 Day Avg. Volume711,483
30 Day Avg. Volume654,186
Financial Highlights & Ratios
PEG Ratio0.59
Price to Book (P/B)-10.94
Price to Sales (P/S)31.19
P/FCF Ratio-27.22
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€55.00Price Target Upside91.64% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.2
Revenue Forecast (FY)€34.72M
Bulls Say, Bears Say
Bulls Say
Strategic Partnership With JanssenA global strategic collaboration with Janssen provides structural funding pathways (upfront, milestones, royalties) and access to a large commercialization engine. That reduces single-company execution risk, creates non-dilutive milestone funding options and materially improves long-term commercialization odds.
Proprietary Nanoparticle PlatformThe hafnium-oxide nanoparticle platform (NBTXR3) is a differentiated mechanism that enhances radiotherapy and can stimulate anti-tumor immunity. Platform-level differentiation supports multiple indication expansion, recurring partnership/licensing opportunities, and durable IP-driven competitive advantage if clinical results translate to approvals.
High Gross Margin On Recent Revenue ReboundA sharp 2025 revenue rebound combined with a reported 100% gross margin indicates attractive unit economics for realized sales or partner-recognized revenue. If sustained, this implies scalable product economics and strong incremental profitability potential when fixed costs and R&D are covered.
Bears Say
Persistent Cash BurnConsistent negative operating and free cash flow means the business lacks internal funding capacity and will likely rely on external financing or partner payments. Over months, this elevates dilution or leverage risk and constrains the company’s ability to self-fund trials and commercialization activities without external support.
Negative Shareholders' Equity And Rising DebtA negative equity base combined with rising debt materially weakens financial flexibility, increases refinancing and covenant risk, and raises the cost of capital. This structural weakness limits the firm's ability to absorb setbacks, negotiate favorable partner terms, or pursue opportunistic investments without external support.
Volatile, Unstable Revenue And EarningsHighly volatile annual revenue with prior negative figures and continued large net losses undermines predictability of cash flows and makes multi-period planning difficult. Even with 2025 growth, inconsistent top-line performance signals execution or demand uncertainty that could impede sustainable commercialization.
NANO FAQ
What was Nanobiotix SA’s price range in the past 12 months?
Nanobiotix SA lowest stock price was €3.75 and its highest was €47.66 in the past 12 months.
What is Nanobiotix SA’s market cap?
Nanobiotix SA’s market cap is €1.53B.
When is Nanobiotix SA’s upcoming earnings report date?
Nanobiotix SA’s upcoming earnings report date is Sep 30, 2026 which is in 101 days.
How were Nanobiotix SA’s earnings last quarter?
Currently, no data Available
Is Nanobiotix SA overvalued?
According to Wall Street analysts Nanobiotix SA’s price is currently Undervalued.
Does Nanobiotix SA pay dividends?
Nanobiotix SA does not currently pay dividends.
What is Nanobiotix SA’s EPS estimate?
Nanobiotix SA’s EPS estimate is -0.25.
How many shares outstanding does Nanobiotix SA have?
Nanobiotix SA has 50,619,583 shares outstanding.
What happened to Nanobiotix SA’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Nanobiotix SA?
Currently, no hedge funds are holding shares in FR:NANO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Nanobiotix SA
Nanobiotix S.A. is a clinical-stage biotechnology firm dedicated to advancing novel therapeutic solutions for various forms of cancer. At the forefront of its pipeline is NBTXR3, an innovative sterile aqueous suspension crafted from crystalline hafnium oxide nanoparticles. This agent is being developed to address a broad spectrum of malignancies, including soft tissue sarcoma, head and neck, liver, prostate, pancreatic, esophageal, rectal, and non-small cell lung cancers. Nanobiotix S.A. has established a strategic alliance with LianBio to facilitate the development and market introduction of NBTXR3 across several key Asian territories: Greater China, South Korea, Singapore, and Thailand. The company, which was established in 2003, maintains its corporate headquarters in Paris, France.
NANO Stock 12 Month Forecast
Average Price Target
€55.00
▲(91.64% Upside)
Technical Analysis
Innate Pharma SA
―
Transgene
―
OSE Immunotherapeutics SA
―
Cellectis SA
―
MaaT Pharma
―
Options Prices
Currently, No data available
---